Daratumumab with bortezomib, lenalidomide and dexamethasone for previously untreated transplant eligible multiple myeloma

Daratumumab in combination with bortezomib, lenalidomide and dexamethasone is being developed for adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with autologous stem cell transplant (ASCT). Multiple myeloma is an incurable type of cancer which develops when plasma cells inside the bone marrow become cancerous. This results in the excessive and abnormal production of plasma cells that interfere with the production of other cells including the red blood cells and white blood cells. Multiple myeloma can affect several areas of the body and symptoms can include: bone pain; hypercalcaemia; kidney problems; organ damage; and immune issues. Death rate amongst multiple myeloma patients remains high so there is a need to develop additional treatment options for these patients.